Source-grounded facts extracted from SIGA TECHNOLOGIES INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SIGA TECHNOLOGIES INC reported financial results for the three months ended March 31, 2026.
“On May 7, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three months ended March 31, 2026.”
SIGA TECHNOLOGIES INC: Amended and restated bylaws to include exclusive forum provisions for Delaware and federal securities claims (effective 2025-06-10).
“On June 10, 2025, the Board of Directors (the “Board”) of SIGA Technologies, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s Amended and Restated By-laws (as so amended and restated, the “By-laws”), effective as of such date. The amendments provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain state corporate law or shareholder derivative claims, and that the federal district courts of the United States are the exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.”
John M. Keane was appointed as Director at SIGA TECHNOLOGIES INC.
“the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately”
Dr. Jay Varma departed as Director at SIGA TECHNOLOGIES INC.
“Pursuant to the terms of his employment agreement, Dr. Varma’s service on the Company’s Board of Directors also automatically ended effective immediately.”
Dr. Jay Varma was terminated as Executive Vice President and Chief Medical Officer at SIGA TECHNOLOGIES INC.
“On September 23, 2024, the Board of Directors of SIGA Technologies, Inc. (the “Company”) terminated Dr. Jay Varma, effective immediately, other than for cause, from his position as Executive Vice President and Chief Medical Officer of the Company.”
Jay K. Varma departed as Member of the Board of Directors at SIGA TECHNOLOGIES INC.
“On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.”
Jay K. Varma departed as Executive Vice President and Chief Medical Officer at SIGA TECHNOLOGIES INC.
“On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.”
SIGA TECHNOLOGIES INC reported three months ended March 31, 2024 results: revenue $ 25.4, net income $ 10.3, EPS $ 0.14.
“Summary Financial Results ($ in millions, except per share amounts) Three Months Ended March 31 2024 2023 Product sales (1) $ 23.9 $ 5.7 Total revenues $ 25.4 $ 8.3 Operating income (loss) (2) $ 11.3 $ (2.1 ) Income (loss) before income taxes (2) $ 13.2 $ (1.2 ) Net income (loss) $ 10.3 $ (0.9 ) Diluted income (loss) per share $ 0.14 $ (0.01 )”
SIGA TECHNOLOGIES INC amended Amendment with Meridian Medical Technologies, LLC (effective 2024-03-27).
“On March 27, 2024, SIGA Technologies, Inc. (the “Company”) and Meridian Medical Technologies, LLC (“Meridian”) entered into an amendment (the “Amendment”) to the Promotion Agreement”
SIGA TECHNOLOGIES INC reported three and twelve months ended December 31, 2023 results: revenue $131 million in product revenues.
“SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer.”
Diem Nguyen was appointed as Chief Executive Officer at SIGA TECHNOLOGIES INC.
“On January 22, 2024, SIGA Technologies, Inc. (the “Company”) announced the appointment of Diem Nguyen, Ph.D., MBA, as Chief Executive Officer of the Company and a member of the Company’s Board of Directors, in each case, effective as of January 27, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.